Status:
COMPLETED
The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Novartis
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The effect of vildagliptin based treatment versus sulfonylurea based treatment on glycemic variability, oxidative stress, and endothelial function in patients with type 2 diabetes.
Detailed Description
Recently, improved understanding of the incretin effect on the pathophysiology of type 2 diabetes has led to development of new agent for hypoglycemic therapy. Vildagliptin is a potent and highly sele...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 diabetic patients with hemoglobin A1c levels within the range 7% - 10%
Exclusion
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT01404676
Start Date
June 1 2010
End Date
May 1 2012
Last Update
September 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, South Korea, 135-710